These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32846177)

  • 1. Biomedical application, drug delivery and metabolic pathway of antiviral nanotherapeutics for combating viral pandemic: A review.
    Mukherjee S; Mazumder P; Joshi M; Joshi C; Dalvi SV; Kumar M
    Environ Res; 2020 Dec; 191():110119. PubMed ID: 32846177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.
    Asrani P; Hasan GM; Sohal SS; Hassan MI
    OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
    Bchetnia M; Girard C; Duchaine C; Laprise C
    J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can nanotechnology help to combat COVID-19? Opportunities and urgent need.
    Campos EVR; Pereira AES; de Oliveira JL; Carvalho LB; Guilger-Casagrande M; de Lima R; Fraceto LF
    J Nanobiotechnology; 2020 Sep; 18(1):125. PubMed ID: 32891146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review.
    Liya G; Yuguang W; Jian L; Huaiping Y; Xue H; Jianwei H; Jiaju M; Youran L; Chen M; Yiqing J
    APMIS; 2020 Jun; 128(6):423-432. PubMed ID: 32363707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.
    Vankadari N
    Int J Antimicrob Agents; 2020 Aug; 56(2):105998. PubMed ID: 32360231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.
    Sharma A; Tiwari S; Deb MK; Marty JL
    Int J Antimicrob Agents; 2020 Aug; 56(2):106054. PubMed ID: 32534188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.